Baseline Systemic Inflammation Response Index and Clinical Outcomes in Heavily Pretreated Platinum-Resistant Ovarian Cancer Treated with Pembrolizumab Monotherapy
Simple Summary Platinum-resistant ovarian cancer is difficult to treat, and the immunotherapy drug pembrolizumab provides long-lasting cancer control in only a small proportion of patients. We investigated whether routine blood tests taken before treatment could provide information about which patients tend to have bet...